Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | DNM1L | O00429 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929684 | 1.00 | PIM1 (0.43) | PIM1PIM3PIM2RAB9ASMN1; SMN2 | |
| SCHEMBL20850964 | 1.00 | PIM1 (0.43) | PIM1PIM3PIM2RAB9ASMN1; SMN2 | |
| SCHEMBL19929685 | 1.00 | PIM1 (0.43) | PIM1PIM3PIM2RAB9ASMN1; SMN2 | |
| SCHEMBL18601672 | 1.00 | PIM1 (0.43) | PIM1PIM3PIM2RAB9ASMN1; SMN2 | |
| SCHEMBL996815 | 0.83 | LDHA (0.51) | PIM1PIM3PIM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL11912169 | 0.82 | PIM1 (0.44) | PIM1PIM3PIM2RAB9ASMN1; SMN2 | |
| SCHEMBL28264041 | 0.82 | PIM1 (0.46) | PIM1PIM3PIM2RAB9AALDH1A1 | |
| SCHEMBL2554941 | 0.82 | PIM1 (0.46) | PIM1PIM3PIM2RAB9AALDH1A1 | |
| SCHEMBL1247127 | 0.81 | LDHA (0.49) | PIM1PIM3PIM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2143075 | 0.78 | CASP8 (0.47) | PIM1PIM3PIM2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | PIM1 3991/4885PIM3 3674/4885PIM2 3413/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | PIM1 3991/4885PIM3 3674/4885PIM2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.